Skip to main content

Tinea Capitis

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
2
Terbinafine hydrochloridePhase 31 trial
Terbinafine hydrochloridePhase 31 trial
Active Trials
NCT00117754Completed720Est. Apr 2006
NCT00117767Completed720
Novartis
NovartisBASEL, Switzerland
2 programs
Terbinafine hydrochloridePHASE_3
Terbinafine hydrochloridePHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozTerbinafine hydrochloride
SandozTerbinafine hydrochloride

Clinical Trials (2)

Total enrollment: 1,440 patients across 2 trials

NCT00117754SandozTerbinafine hydrochloride

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Start: Jul 2004Est. completion: Apr 2006720 patients
Phase 3Completed
NCT00117767SandozTerbinafine hydrochloride

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Start: Jun 2004720 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.